Chiara Pirrone

Medical Doctor & Oncology Resident @SanMartino_Ge

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Lorenza Rimassa @LorenzaRimassa]

Oral presentations on biliary tract cancer at @AIOMtweet annual congress.
Congratulations to Chiara Pirrone and Virginia Genovesi for their studies on #BTC #CCA!
@casadei_gardini
@HUNIMED @HumanitasMilano

[andrea casadei gardini @casadei_gardini]

Our new study in EJC explores pathway-level genomic alterations in biliary tract cancer treated with cisplatin, gemcitabine & durvalumab.
HRD/BRCAness, TGF-β, and high TMB emerge as prognostic biomarkers.
🔗 https://t.co/8nfSDpVL2y
#BTC #Cholangiocarcinoma #Immunotherapy #Oncolog

[andrea casadei gardini @casadei_gardini]

Our last paper…fantastic international collaboration
-CisGem durvalumab in BTC patients 
-666 patients: median OS of 15.1 months and median PFS of 8.2 months
-The results confirmed the results achieved in the TOPAZ-1 trial
https://t.co/QmOW3dIN2u

[andrea casadei gardini @casadei_gardini]

Durvalumab GC (350 pt) vs GC (213 pt)in Biliary Tract Cancer (RWD)
Our last paper 🎉
-Cis Gem Durva OS 14.8 months versus Cis Gem 11.2 months [HR 0.63 p = 0.0002]…and many other results 😎
@MargheRimini @LorenzaRimassa @Mom_enji @sara_lonardi1

https://t.co/pFyhdTucFx

[andrea casadei gardini @casadei_gardini]

Our last paper—> Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data

@LorenzaRimassa @sara_lonardi1 @Mom_enji @fedenichetti

https://t.co/5aHbvCT7Bd